Quintrio
Home

Stock overview

Bright Minds Biosciences Inc. Common Stock

DRUG

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Last trade $20.29
Day change -$2.32 (-10.26%)
Day range $20.07 – $22.76
Volume 112,805
Market cap $223M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for DRUG.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for DRUG.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company also granted 109,000 stock options to directors, officers, and consultants at an exercise price of US$83.40 per share, vesting over four years.

The Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

B Group, Inc. initiated a new position in Bright Minds Biosciences by purchasing 67,500 shares worth approximately $5.43 million in Q1 2026. The investment signals confidence in the company's epilepsy drug pipeline, particularly BMB-101. Bright Minds is a pre-clinical biotech firm with a well-funded balance sheet (C$309.7 million in cash) and no commercial revenue, representing a high-risk, high-reward opportunity for long-term investors.

Benzinga

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences (NASDAQ: DRUG) successfully closed a public offering of 1.945 million common shares at US$90 per share, raising US$175.05 million in gross proceeds. The company plans to use the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, Prader-Willi Syndrome, and BMB-105, along with R&D and general corporate purposes.

GlobeNewswire Inc.

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences priced an upsized public offering of 1,945,000 common shares at $90 per share for gross proceeds of $175.05 million. The company plans to use net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as phase 1 trials for BMB-105. The offering is expected to close on January 9, 2026.

The Motley Fool

Why Bright Minds Biosciences Stock Topped the Market on Monday

Bright Minds Biosciences strengthened its scientific advisory board with four experts in Prader-Willi Syndrome, launching a new investigational drug program targeting the rare genetic disorder. The company will evaluate existing and new treatment candidates, with initial Phase 1 studies focusing on safety and tolerability.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 14, 20231-for-5reverse split